The popularity of Sildenafil initially fueled a period of growth for major pharmaceutical companies, however recent developments present a murky scenario for investors. Lower-cost competitors are eating into revenue, https://rebeccaidhn588859.dbblog.net/14486675/viagra-and-pharma-a-risky-investment